(HealthDay News) — A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced genitourinary (GU) toxicity in patients ...

A 25th anniversary launch party for Ottawa’s Ride for Dad was held Thursday, May 1, at The Joint inside Rideau Carleton ...

New approval provides hospitals and clinics in the Czech Republic with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, May 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] ...

The researchers found that, across the United States, the number of men with low-risk cancer getting surgery dropped more ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line ...

The British monarch, 76, used the message to share his experiences of the disease, which he said showed him "the very best of humanity." The statement was issued to attendees of an April 30 reception ...

King Charles delivered his most personal public remarks since being diagnosed with cancer, addressing guests at a Buckingham ...

Britain's King Charles on Wednesday said his cancer diagnosis had been an experience that showed him "the very best of ...

Further diagnostic tests revealed that Charles has “a form of cancer.” In the months since the announcement, no further ...

The new technique is now the 'prime candidate' for potential clinical trials, raising hopes that for the first time, a ...

Illuccix’s broad approval is supported by robust clinical data, including the largest Ga-68-based PSMA data set from the VISION trial 6. The approval of Illuccix® in France has the potential to ...